Liminatus Pharma issues 4M shares to settle $7.5M default judgment, dismisses lawsuits

Liminatus Pharma, Inc.

Issued 4,000,000 shares to Clear Street LLC in exchange for surrender of 805,377 warrants.
Settles default judgment of $7.5M plus approximately $515K interest from September 2025.
Dismisses two federal lawsuits: Central District of California and Southern District of New York.
Unregistered issuance under Section 3(a)(9) of the Securities Act; no commissions paid.

item 1.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liminatus Pharma, Inc. entered into Settlement Agreement with Clear Street LLC (effective 2026-02-06).

Action: entry
Agreement: settlement
Counterparty: Clear Street LLC
Effective: 2026-02-06

Exact text from the filing

On February 6, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Clear Street LLC (the “Holder”), pursuant to which the Company agreed to issue 4,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 805,377 warrants (the “Warrants”) to purchase shares of Common Stock held by the Holder.

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

Liminatus Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-012016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.